戴纳基Dyne Therapeutics宣布,其药物候选产品Dyne-251已获得日本监管部门的孤儿药认定,该药物用于治疗杜氏肌营养不良症。这一认定为公司在日本市场推进该治疗方案的开发提供了重要的监管支持。
戴纳基Dyne Therapeutics宣布,其药物候选产品Dyne-251已获得日本监管部门的孤儿药认定,该药物用于治疗杜氏肌营养不良症。这一认定为公司在日本市场推进该治疗方案的开发提供了重要的监管支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.